Skip to content

Investigating the protective effects of Grape Seed tablets nephrotoxicity caused by contrast in patient who undergo imaging with contrast agent

Investigating the protective effects of Grape Seed tablets on nephrotoxicity caused by contrast in patients who undergo imaging with contrast agents

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250302064895N1
Enrollment
60
Registered
2025-03-21
Start date
2025-02-17
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast-induced nephropathy. Contrast-induced nephropathy

Interventions

Intervention 1: Intervention group: Saline (0.45%) was given intravenously at a rate of 1 ml per kg of body weight per hour and grapefruit seed extract was given orally at a dose of 500 mg 6 hours bef
Ultravist-300, brand name Visipaqe) was 75 ml for all patients. Intervention 2: Control group: Saline (0.45%) was given intravenously at a rate of 1 ml per kg body weight per hour and placebo was give

Sponsors

Arak University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: age over 18 years People with a glomerular filtration rate between 30 and 60 Absence of acute renal failure at baseline

Exclusion criteria

Exclusion criteria: The patient's unwillingness to continue cooperating Patients taking nephrotoxic drugs including vancomycin, aminoglycosides, colistin Patients with multiple myeloma

Design outcomes

Primary

MeasureTime frame
Protective effect of grapefruit seed extract on the prevention of contrast-induced nephrotoxicity. Timepoint: Serum creatinine measurement before the start of the intervention and 48 hours after the intervention. Method of measurement: Serum creatinine measurement.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamia Shabib

Arak University of Medical Sciences

Shabib333@gmail.com+98 86 3417 3601

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026